What % BF do you think you're at? Are you doing cardio? Also, what sides are associated with this injectable L-car?
i dont know maybe at between 17-25% bf lol
in my next post im going to put some pics i got on my Havoc Log
Heres some info regardin cardispan
Pharmaceutical Form And Formula:
Injectable Cardispan
Each vial contains:
Levocarnitine 1g
Vehicle, q.s. 5 ml.
Therapeutic indications:
Cardispan* is indicated in the treatment of Levocarnitine deficiency, which may be primary (Cardiomyopathies, myopathies, innate errors of the metabolism and muscular dystrophy) or secondary, such as in those conditions where it is required to increase the production of corporal energy by means of the utilization of fatty acids as an energy source. Secondary deficiency exists due to: lack of synthesis and/or supply (artificial nutrition, malnutrition or poor eating habits, premature babies, neonatal infants and underweight children, newborns fed on soy or casein formulas, strict vegetarianism, and hepatic cirrhosis).
Consumption of levocarnitine (chronic and acute myocardic ischemia: myocardium infarct, angina pectoris, congestive cardiac insufficiency, arrhythmias, myocardiumsclerosis, senile heart, aortocoronary bypass surgery, peripheral vascular disease, and patients in rehabilitation or physical conditioning).
Loss of levocarnitine (renal insufficiency treated with dialysis or hemodialysis, hypercatabolic conditions, such as sepsis, burns, major traumatisms or surgeries, hyperthyroidisms, pregnancy, secondary cardiomyopathies from the use of tricyclic antidepressants, valporic acid or antineoplastics).
Endocrines and metabolic alterations (diabetes mellitus, diabetic ketoacidosis, hyperlipoproteinemia, endogenous obesity, hypothyroidism, hipopituitarism, Addison's disease and Cushing syndrome).
Other uses: In sports medicine the levocarnitine is utilized as a ergogenic substance and nutritional supplement in healthy persons who perform sports activities. Due to its role in the lipids metabolism, it is used as an aid in the medical management of weight control in patients with exogenous obesity due to the excessive ingestion and disorder of foods.
Pharmacokinetics and pharmacodynamics:
Cardispan* levocarnitine, a natural constituent of the human organism.
Only the levogiration isomer is biologically active. It plays an essential role in the metabolism for the production of energy. The betaoxidation of mitochondrial fatty acids is the greatest and most efficient source of energy (ATP), but in order to produce it, it requires essential transport, levocarnitine, being a physiological substance which generates energy upon transporting fatty acids of the cytosol to the mitochondrial hue where the betaoxidation is performed with the production of acetyl coenzyme A and ATP by means of the mitochondria cycle. Wherefore the levocarnitine is essential for the provision of energetic substrate, principally in myocardium and skeletal muscle; its deficiency causes significant alterations in the lipids metabolism, due both to a energy production deficiency as well as an accumulation of triglycerides and free fatty acids.
Ischemia and intense physical activity provoke significant metabolic changes, given the existence of an increase of energy requirements. Such conditions result in a great loss and/or increase in the demand for levocarnitine for the metabolic utilization of lipids, ketene bodies and amino acid chains. Tissue deficiency of levocarnitine is identified in patients with acute or chronic ischemia and in persons after physical activity. Levocarnitine is a natural compound which improves cardiovascular function and increases physical performance, improving ergometric evaluations.
When an imbalance exists between the supply of energetic nutrients and the demand of ATP, an energy crisis exists. In children, the demands for energy increase during growth, sports requirements, fasting, fever, infections and convalescence. Levocarnitine and energy deficiency are caused a low pondostatural rate, lack of progress in development, low appetite, repeated infections, apathy, disinterest, lethargy, low sports performance, weakness and underdeveloped muscles.
Levocarnitine is naturally acquired by the ingestion of foods, above all foods of animal origin, and it can be synthesized in the liver and kidneys from methionine and lysia amino acids. Levocarnitine is absorbed in the small intestine, principally in jejunum. It enters into the circulation and is widely distributed throughout the organism. Its presence in tissues suggests the existence of a cellular system of selective capture in myocardium skeletal muscles, as well as in the liver and kidneys. Most of the corporal levocarnitine is excreted in the urine and feces.
Contraindications:
Hypersensitivity to levocarnitine.
General precautions:
Being a substance which normally exists in the organism, it does not cause adverse effects, even at doses as high as 15g per day.
Restrictions of use during pregnancy and breastfeeding:
There exist no restrictions of use during pregnancy or breastfeeding. In actual fact, the requirements are found to be increased under such conditions. Levocarnitine is a normal component of maternal milk.
Side effects and adverse effects:
Daily doses over 3 to 5g daily in adults are associated with softening of the feces and, in some cases, the presence of diarrhea with no clinical significance.
No other adverse events have been reported with the administration of levocarnitine.
Interactions with medicines or other substances:
None have been reported up to the present date.
Alterations in the results of laboratory testing:
None have been reported up to the present date.
Precautions regarding effects of carcinogenesis, mutagenesis, teratogenesis and on fertility:
Studies have shown that levocarnitine is not mutagenic, teratogenic, and that it does not affect fertility. Studies on carcinogenesis have not been performed given that levocarnitine is a natural constituent in humans.
Doses and means of administration:
The recommended dose is of 50 mg per kg of weight per day divided into 2 or 3 doses, but it may be increased or decreased according to the clinical response and criteria of the doctor. In general, 3 to 5 g per day are administered to adults, and half of such dosage is administered to children. In children with primary deficiencies of levocarnitine, 100 g per kg of weight are used per day. The injectable solution may be administered intramuscularly or intravenously. If the latter is preferred, it may be applied directly or diluted in intravenous solutions. The use of injectable Cardispan* is suggested in artificial nutrition, acute myocardic ischemia and renal insufficiency treated with dialysis or hemodialysis. Cardispan* oral solution at 30% is recommended for chronic myocardic ischemia and peripheral vascular disease. In children with malnutrition, premature babies, neonatal infants and underweight children, the presentation of Cardispan* pediatric solution at 10% is ideal. In sports medicine, endogenous obesity and for patients in rehabilitation or physical conditioning, the use of Cardispan* chewable tables is advised.
Manifestations and handling of overdosing and accidental ingestion:
No cases of overdosing of this product have been reported.
Presentations:
Cardispan* Injectable solution: Box with 5 vials of 1g of levocarnitine each.
Storage recommendations:
Store in a fresh dry place.
